Global Hormone Replacement Therapy Market Size By Product (Thyroid Hormone Replacement Therapy, Testosterone Replacement Therapy), Route of Administration (Oral, Transdermal), Disease Type (Menopause, Hypothyroidism), By Geographic Scope And Forecast

Hormone Replacement Therapy Market Size And Forecast

Hormone Replacement Therapy Market size was valued at USD 16.14 Billion in 2021 and is projected to reach USD 27.65 Billion by 2030, growing at a CAGR of 6.45% from 2023 to 2030.

The Hormone Replacement Therapy Market is observing growth owing to the factors such as the availability of long-acting hGH products and the rising incidence of target diseases. Moreover, rising hormone deficiencies and public awareness of diseases are also estimated to promote market growth. The Global Hormone Replacement Therapy Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Hormone Replacement Therapy Market Definition

Hormone replacement therapy (HRT) is the therapy of replacement of natural hormones when the body is not able to produce enough naturally. Such as, hormone replacement therapy can be delivered to human growth hormone patients and thyroid patients. Moreover, HRT was recommended normally to menopausal women for the relief from their symptoms such as sleep disturbances, night sweats, hot flushes, psychological & genito-urinary problems (vaginal dryness and urinary frequency), and for the prevention of osteoporosis.

In recent years, hormone replacement therapy is broadly used for the treatment of disorders related to menopause in women, which is leading to the reduction of risks of osteoporosis, hot flashes, and other menopause symptoms. Therefore, disorders such as thyroid disorders, growth deficiency, and others are also anticipated to surge the growth of the global market over the forecast period.

Global Hormone Replacement Therapy Market Overview

Certain factors are positively influencing the growth of the Hormone Replacement Therapy Market increase in drug development with new delivery systems, growing awareness of post-menopausal issues amongst women, and hormonal imbalance disorders along with the growing geriatric population. As per the 2022 World Population Prospects report, the United States, the latest estimates by the United Nations proposed that the global population could reach about 8.5 billion by 2030, 9.7 billion by 2050, and 10.4 billion by 2100.

With several types of hormonal changes, the woman’s body mostly gets impacted by the natural process of aging, resulting in diseases and abnormalities. But, these products can also have side effects, such as a rise in blood clots, cholesterol levels, swelling, bloating, and others, which might hamper the growth of the market. In addition, product recalls, delays in FDA approvals, stringent regulations, and other such factors may also hinder the development of the Hormone Replacement Therapy Market.

The other key factors driving hormone replacement therapy are the growing importance of regenerative prescriptions, for instance, against conceptive and maturing cycle-supporting therapy such as menopausal hormone replacement. The growing interest in other restorative regions, for instance, thyroid hormone therapy and growth hormone therapy due to the nearly safe proficiency, profile, and cost viability of such medications is expected to impact the market development.

Global Hormone Replacement Therapy MarketSegmentation Analysis

The Global Hormone Replacement Therapy Market is Segmented on the basis of Product, Route of Administration, Disease Type, And Geography.

Hormone Replacement Therapy Market, By Product

• Estrogen and Progesterone Replacement Therapy
• Human Growth Hormone (HGH) Replacement Therapy
• Thyroid Hormone Replacement Therapy
• Testosterone Replacement Therapy

Based on Product, the market is segmented into Estrogen and Progesterone Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Hormone Replacement Therapy, And Testosterone Replacement Therapy. The Estrogen & Progesterone Replacement Therapy segment dominated the market for Hormone Replacement Therapy in 2021. The dominance is owing to an increase in the awareness associated with menopause symptoms around the world, a rise in the adoption of such improved treatments, and the availability of such drugs in several formulations. In September 2021, Theramex produced Bijuve/Bijuva, the first body alike Estrogen & Progesterone hormone therapy for post-menopausal women in the regions such as European and U.K. These launches are anticipated to boost the segment’s growth.

Hormone Replacement Therapy Market, By Route of Administration

• Oral
• Parenteral
• Transdermal
• Others

Based on Route of Administration, the market is segmented into Oral, Transdermal, Parenteral, and Others. Among these, Oral holds a prominent market share, due to the surge in adoption of the oral medications worldwide and the huge production of oral medications by the major players in the market. Moreover, the fact that the oral route is the most favored route for oral medication, as well as testosterone drugs, is expected to drive the growth of the segment in the Hormone Replacement Therapy Market.

Hormone Replacement Therapy Market, By Disease Type

• Menopause
• Hypothyroidism
• Growth Hormone Deficiency
• Others

Based on Disease Type, the market is segmented into Menopause, Hypothyroidism, Growth Hormone Deficiency, and Others. The Menopause segment dominated the market for Hormone Replacement Therapy in 2021 owing to the surge in the number of women facing menopausal issues. As per the UN’s 2020 global projections, 958 million women were aged over 50. By 2050, this number is anticipated to reach about 1.65 million. Many women are expected to spend over one-third of their lives after menopause over the coming years.

Hormone Replacement Therapy Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Based on Regional Analysis, the Global Hormone Replacement Therapy Market is classified into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The North American region has the greatest market share and is expected to grow at the highest CAGR over the forecast period. Favorable reimbursement policies, collaborative agreements between manufacturers, and major product launches are among the factors leading to the largest market share of the region. In August 2020, the Sogroya (somapacitan-beco) received U.S. FDA approval, an HGH replacement treatment product manufactured by Novo Nordisk A/S. This product is given once a week via a subcutaneous route in adults detected with growth hormone deficiency.

Key Players

The “Global Hormone Replacement Therapy Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as Pfizer Inc., Merck & Co. Inc., Bayer AG, Viatris Inc., ASCEND Therapeutics US LLC, Novo Nordisk A/S, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Noven Pharmaceuticals Inc., AbbVie Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In February 2022, Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
• In May 2021, Myovant Sciences GmbH announced that it received approval from the U.S. FDA for its hormone therapy Myfembree as a treatment for uterine fibroid bleeding. The drug launched by Myovant will give direct competition to AbbVie with an added dosing advantage.
• In April 2021, TherapeuticsMD, Inc., and Theramex announced that they received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Federal Agency of Medicines and Health Products (FAMHP) for the use of BIJUVE in the U.K and under BIJUVA trade name in Belgium. The capsule will be used as hormone replacement therapy.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Hormone Replacement Therapy Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. Porter’s five forces model can be used to assess the competitive landscape in Global Hormone Replacement Therapy Market gauge the attractiveness of a certain sector, and assess investment possibilities.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Metho